A Two-Part, Open-label, Sequential, Double Cohort, Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Rosuvastatin When Co Administered With Darapladib in Healthy Adult Subjects
Phase of Trial: Phase I
Latest Information Update: 28 Jul 2017
Price : $35 *
At a glance
- Drugs Darapladib (Primary) ; Rosuvastatin (Primary)
- Indications Atherosclerosis; Cardiovascular disorders; Diabetic macular oedema; Hypercholesterolaemia; Hyperlipidaemia; Hypertriglyceridaemia
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline
- 01 Mar 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 16 Jan 2013 New trial record
- 01 Dec 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.